{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T10:02:48Z","timestamp":1751536968457,"version":"3.33.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2022YFC2703100"],"award-info":[{"award-number":["2022YFC2703100"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-002"],"award-info":[{"award-number":["2022-PUMCH-D-002"]}]},{"name":"Xiong'an New Area Science and Technology Innovation Special Project","award":["2023XAGG0069"],"award-info":[{"award-number":["2023XAGG0069"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>There is no unified prognostic scoring system for light chain cardiac amyloidosis (AL-CA), particularly stage IIIb AL-CA. This study aimed to use invasive haemodynamic information to investigate markers that can more accurately evaluate the prognosis of patients with stage IIIb AL-CA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this retrospective cohort study, we conducted invasive haemodynamic measurements concurrently with myocardial biopsies to diagnose AL-CA. We used Cox regression analysis and time-dependent receiver operating characteristic curve analysis to study the associations between these measurements and overall mortality. Echocardiographic parameters were also recorded and analysed via logistic regression to explore their relationships with haemodynamic changes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Although traditional haemodynamic parameters, such as the cardiac index (CI), pulmonary artery wedge pressure (PAWP), pulmonary artery pressure, and vascular resistance, did not correlate with mortality, the PAWP\/CI ratio emerged as a vital prognostic marker. Patients with a PAWP\/CI ratio above 11\u00a0mmHg\/L\/min\/m<jats:sup>2<\/jats:sup> had markedly poorer survival. Kaplan\u2012Meier analysis highlighted the prognostic significance of the ratio, revealing distinct survival differences. Furthermore, logistic regression confirmed that echocardiographically measured pulmonary artery systolic pressure independently correlated with increases in the PAWP\/CI ratio.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In stage IIIb AL-CA patients, the PAWP\/CI ratio, which surpasses traditional haemodynamic indicators, significantly predicts all-cause mortality, emphasizing its prognostic value. Our findings suggest that echocardiography-derived PASP could alternatively reflect the PAWP\/CI ratio.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-024-03451-z","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T10:32:42Z","timestamp":1736764362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Improving prognostic evaluations in patients with stage IIIb light chain cardiac amyloidosis: role of haemodynamic parameters"],"prefix":"10.1186","volume":"20","author":[{"given":"Jingyi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1140-4062","authenticated-orcid":false,"given":"Zhuang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"25","key":"3451_CR1","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1200\/JCO.2013.50.0892","volume":"32","author":"BM Weiss","year":"2014","unstructured":"Weiss BM, Hebreo J, Cordaro DV, Roschewski MJ, Baker TP, Abbott KC, Olson SW. Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. J Clin Oncol. 2014;32(25):2699\u2013704.","journal-title":"J Clin Oncol"},{"key":"3451_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","volume":"71","author":"J Rubin","year":"2020","unstructured":"Rubin J, Maurer MS. Cardiac amyloidosis: overlooked, underappreciated, and treatable. Annu Rev Med. 2020;71:203\u201319.","journal-title":"Annu Rev Med"},{"issue":"3","key":"3451_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","volume":"94","author":"RA Kyle","year":"2019","unstructured":"Kyle RA, Larson DR, Kurtin PJ, Kumar S, Cerhan JR, Therneau TM, Rajkumar SV, Vachon CM, Dispenzieri A. Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc. 2019;94(3):465\u201371.","journal-title":"Mayo Clin Proc"},{"issue":"17","key":"3451_CR4","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","volume":"121","author":"AD Wechalekar","year":"2013","unstructured":"Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420\u20137.","journal-title":"Blood"},{"key":"3451_CR5","first-page":"220","volume":"109","author":"S Oubari","year":"2023","unstructured":"Oubari S, Hegenbart U, Schoder R, Steinhardt M, Papathanasiou M, Rassaf T, Thimm A, Hagenacker T, Naser E, Duhrsen U, et al. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival. Haematologica. 2023;109:220.","journal-title":"Haematologica"},{"issue":"18","key":"3451_CR6","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751\u20137.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3451_CR7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989\u201395.","journal-title":"J Clin Oncol"},{"issue":"45","key":"3451_CR8","doi-asserted-by":"publisher","first-page":"4736","DOI":"10.1093\/eurheartj\/ehac526","volume":"43","author":"T Damy","year":"2022","unstructured":"Damy T, Zaroui A, Oghina S. The challenge of managing patients with light-chain cardiac amyloidosis: the value of cardiac magnetic resonance as a guide to the treatment response. Eur Heart J. 2022;43(45):4736\u20138.","journal-title":"Eur Heart J"},{"issue":"8","key":"3451_CR9","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.jcmg.2021.01.016","volume":"14","author":"PR Huntjens","year":"2021","unstructured":"Huntjens PR, Zhang KW, Soyama Y, Karmpalioti M, Lenihan DJ, Gorcsan J 3rd. Prognostic utility of echocardiographic atrial and ventricular strain imaging in patients with cardiac amyloidosis. JACC Cardiovasc Imaging. 2021;14(8):1508\u201319.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"3451_CR10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","volume":"126","author":"G Palladini","year":"2015","unstructured":"Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, Basset M, Hawkins P, Merlini G, Wechalekar AD. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612\u20135.","journal-title":"Blood"},{"issue":"1","key":"3451_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","volume":"32","author":"C Mitchell","year":"2019","unstructured":"Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, Horton K, Ogunyankin KO, Palma RA, Velazquez EJ. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American society of echocardiography. J Am Soc Echocardiogr. 2019;32(1):1\u201364.","journal-title":"J Am Soc Echocardiogr"},{"issue":"38","key":"3451_CR12","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618\u2013731.","journal-title":"Eur Heart J"},{"issue":"3","key":"3451_CR13","doi-asserted-by":"publisher","first-page":"e010078","DOI":"10.1161\/CIRCHEARTFAILURE.122.010078","volume":"16","author":"P Martens","year":"2023","unstructured":"Martens P, Bhattacharya S, Longinow J, Ives L, Jacob M, Valent J, Hanna M, Tang WHW. Hemodynamic profiling and prognosis in cardiac amyloidosis. Circ Heart Fail. 2023;16(3):e010078.","journal-title":"Circ Heart Fail"},{"key":"3451_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/ajh.27179","volume":"99","author":"R Chakraborty","year":"2023","unstructured":"Chakraborty R, Bhutani D, Mapara M, Reshef R, Maurer MS, Radhakrishnan J, Lentzsch S. Reduced early mortality with daratumumab-based frontline therapy in AL amyloidosis: a retrospective cohort study. Am J Hematol. 2023;99:477\u20139.","journal-title":"Am J Hematol"},{"issue":"4","key":"3451_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3109\/13506129.2013.821406","volume":"20","author":"C Russo","year":"2013","unstructured":"Russo C, Green P, Maurer M. The prognostic significance of central hemodynamics in patients with cardiac amyloidosis. Amyloid. 2013;20(4):199\u2013203.","journal-title":"Amyloid"},{"issue":"8","key":"3451_CR16","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1136\/hrt.2010.212084","volume":"97","author":"S Janda","year":"2011","unstructured":"Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Heart. 2011;97(8):612\u201322.","journal-title":"Heart"},{"issue":"3","key":"3451_CR17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1378\/chest.14-1335","volume":"147","author":"S Krishnan","year":"2015","unstructured":"Krishnan S, Schmidt GA. Acute right ventricular dysfunction: real-time management with echocardiography. Chest. 2015;147(3):835\u201346.","journal-title":"Chest"},{"issue":"7","key":"3451_CR18","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1182\/blood-2015-08-618561","volume":"127","author":"VR Gordeuk","year":"2016","unstructured":"Gordeuk VR, Castro OL, Machado RF. Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood. 2016;127(7):820\u20138.","journal-title":"Blood"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03451-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03451-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03451-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T23:22:46Z","timestamp":1736810566000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03451-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3451"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03451-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"9 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board for Clinical Research of Peking Union Medical College Hospital (I-24PJ0065). All subjects were well informed about the study and potential risk and signed an informed consent before participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}